Alzamend Neuro
ALZN | NASDAQ
$1.18
-$0.06 (-4.84%)
At close: Nov 16, 2026, 4:00 PM ET
$1.16
-$0.02 (-1.69%)
After-hours:
Nov 16, 2026, 6:04 PM ET
-4.84%
(1D)No price chart data available for 1D timeframe.
Rating
39
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #549/1021 (Top 54%)
Key Statistics
Market Data
Market Cap $5.69M
1D Range
1.11 1.28
52W Range
0.86 2.44
Valuation (TTM)
PE -0.51
PB 0.98
EV/EBITDA 0.21
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $26.00
Cash Flow
FCF Yield -120.2%
SBC Adj. FCF Yield -122.3%
SBC Impact -1.7%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 131.0% |
56.8%
FCF 3Y | 5Y -5.2% |
5.3%
Returns
ROA -106.5%
ROE -277.9%
ROIC -156.7%
Financial Health
Net Cash
$7.59M
Current Ratio 3.01
Interest Coverage 818.59
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, ...
Sector Healthcare
Industry Biotechnology
Employees 6
IPO Date Jun 15, 2021
Website www.alzamend.com
Fiscal Year May - April
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$26.00
Upside
+2103.39%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ALZN